Alrouji Mohammed, Manouchehrinia Ali, Aram Jehan, Alotaibi Abdulmajeed, Alhajlah Sharif, Almuhanna Yasir, Alomeir Othman, Shamsi Anas, Gran Bruno, Constantinescu Cris S
Clinical Neurosciences Group, Shaqra University, Shaqra 11961, Saudi Arabia.
Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.
Brain Sci. 2023 May 15;13(5):800. doi: 10.3390/brainsci13050800.
The present study is aimed at determining the effect of cigarette smoking (CS) on serum uric acid (UA) levels quantitatively before and after smoking cessation among people with MS (pwMS). Additionally, a possible correlation between UA levels and both disability progression and disease severity was also investigated. A retrospective cross-sectional study was conducted using the Nottingham University Hospitals MS Clinics database. It involves 127 people with definite MS recorded when reporting the latest smoking status and the clinical diagnosis. All necessary demographics and clinical characteristics were collected. We found that smoker pwMS had significantly lower serum UA levels than non-smoker pwMS (-value = 0.0475), and this reduction was recovered after smoking cessation (-value = 0.0216). However, the levels of disability or disease severity were not correlated with the levels of serum UA in current smoker pwMS, measured by the expanded disability status scale (EDSS; r = -0.24; -value = 0.38), multiple sclerosis impact scale 29 (MSIS-29; r = 0.01; -value = 0.97) and MS severity score (MSSS; r = -0.16; -value = 0.58), respectively. Our result suggests that the reduction in UA levels is more likely a consequence of oxidative stress triggered by many risk factors, including CS, and could be considered a potential indicator of smoking cessation. In addition, the absence of a correlation between UA levels and disease severity and disability suggests that UA is not an optimal biomarker for disease severity and disability prediction among current smoker, ex-smoker or non-smoker pwMS.
本研究旨在定量确定吸烟(CS)对多发性硬化症患者(pwMS)戒烟前后血清尿酸(UA)水平的影响。此外,还研究了UA水平与残疾进展和疾病严重程度之间的可能相关性。使用诺丁汉大学医院多发性硬化症诊所数据库进行了一项回顾性横断面研究。该研究纳入了127名在报告最新吸烟状况和临床诊断时确诊为多发性硬化症的患者。收集了所有必要的人口统计学和临床特征。我们发现,吸烟的pwMS患者血清UA水平显著低于不吸烟的pwMS患者(P值 = 0.0475),戒烟后这种降低情况得到恢复(P值 = 0.0216)。然而,通过扩展残疾状态量表(EDSS;r = -0.24;P值 = 0.38)、多发性硬化症影响量表29(MSIS - 29;r = 0.01;P值 = 0.97)和多发性硬化症严重程度评分(MSSS;r = -0.16;P值 = 0.58)测量,目前吸烟的pwMS患者的残疾或疾病严重程度水平与血清UA水平无关。我们的结果表明,UA水平降低更可能是包括CS在内的许多危险因素引发的氧化应激的结果,并且可以被视为戒烟的潜在指标。此外,UA水平与疾病严重程度和残疾之间缺乏相关性表明,对于目前吸烟、曾经吸烟或不吸烟的pwMS患者,UA不是疾病严重程度和残疾预测的最佳生物标志物。